Vaccines advisory panel endorses move to trivalent formulation for U.S. flu vaccines


Yesterday, FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) weighed in on strains for seasonal influenza vaccines for the Northern hemisphere 2024-2025 season. The meeting was straightforward, since both industry and FDA are ready ahead of schedule to remove one out-of-circulation influenza strain.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap